Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

Dextrophropoxyphene effects on QTc-interval prolongation: Frequency and characteristics in relation to plasma levels.

Keller GA, Villa Etchegoyen C, Fernandez N, Olivera NM, Quiroga PN, Diez RA, Di Girolamo G.

J Opioid Manag. 2018 Sep/Oct;14(5):335-344. doi: 10.5055/jom.2018.0466.

PMID:
30387857
2.

KIAA1199 expression and hyaluronan degradation colocalize in multiple sclerosis lesions.

Marella M, Jadin L, Keller GA, Sugarman BJ, Frost GI, Shepard HM.

Glycobiology. 2018 Dec 1;28(12):958-967. doi: 10.1093/glycob/cwy064.

3.

Drug-induced QT Interval Prolongation in the Intensive Care Unit.

Etchegoyen CV, Keller GA, Mrad S, Cheng S, Di Girolamo G.

Curr Clin Pharmacol. 2017;12(4):210-222. doi: 10.2174/1574884713666180223123947. Review.

PMID:
29473523
4.
6.

In vivo Phenotyping Methods: Cytochrome P450 Probes with Emphasis on the Cocktail Approach.

Keller GA, Gago MLF, Diez RA, Di Girolamo G.

Curr Pharm Des. 2017;23(14):2035-2049. doi: 10.2174/1381612823666170207100724. Review.

PMID:
28176665
7.

Meperidine-induced QTc-interval prolongation: prevalence, risk factors, and correlation to plasma drug and metabolite concentrations
.

Keller GA, Villa Etchegoyen MC, Fernández N, Olivera NM, Quiroga PN, Diez RA, Di Girolamo G.

Int J Clin Pharmacol Ther. 2017 Mar;55(3):275-285. doi: 10.5414/CP202612.

PMID:
27509828
8.

A Systematic Approach to Assess the Burden of Drug Interactions in Adult Kidney Transplant Patients.

Bril F, Castro V, Centurion IG, Espinosa J, Keller GA, Gonzalez CD, Riera MC, Saubidet CL, Di Girolamo G, Pujol GS, Alvarez PA.

Curr Drug Saf. 2016;11(2):156-63.

PMID:
27194037
9.

Comparative bioavailability of two tablet formulations of emtricitabine/tenofovir in healthy, fasting volunteers: a single-dose, randomized-sequence, open-label crossover study.

Keller GA, Czerniuk P, Bertuola RA, Mendez M, Gimenez MI, Di Girolamo G.

Int J Clin Pharmacol Ther. 2016 Oct;54(10):825-34. doi: 10.5414/CP202540.

PMID:
27049055
10.

Relative bioavailability between two teriparatide formulations in healthy volunteers.

Farías J, Keller GA, Papouchado M, Villa Etchegoyen MC, Criscuolo ME, Diez RA, Di Girolamo G.

Int J Clin Pharmacol Ther. 2016 Aug;54(8):649-56. doi: 10.5414/CP202562.

PMID:
27007999
11.

Tramadol Induced QTc-Interval Prolongation: Prevalence, Clinical Factors and Correlation to Plasma Concentrations.

Keller GA, Etchegoyen MC, Fernandez N, Olivera NM, Quiroga PN, Belloso WH, Diez RA, Di Girolamo G.

Curr Drug Saf. 2016;11(3):206-14.

PMID:
26916784
12.

Drug-Induced QTc Interval Prolongation: A Multicenter Study to Detect Drugs and Clinical Factors Involved in Every Day Practice.

Keller GA, Alvarez PA, Ponte ML, Belloso WH, Bagnes C, Sparanochia C, Gonzalez CD, Villa Etchegoyen MC, Diez RA, Di Girolamo G.

Curr Drug Saf. 2016;11(1):86-98.

PMID:
26537523
13.

Vitamin D3 seems more appropriate than D2 to sustain adequate levels of 25OHD: a pharmacokinetic approach.

Oliveri B, Mastaglia SR, Brito GM, Seijo M, Keller GA, Somoza J, Diez RA, Di Girolamo G.

Eur J Clin Nutr. 2015 Jun;69(6):697-702. doi: 10.1038/ejcn.2015.16. Epub 2015 Mar 18.

PMID:
25782422
14.

Age-distribution and genotype-phenotype correlation for N-acetyltransferase in Argentine children under isoniazid treatment.

Keller GA, Fabian L, Gomez M, Gonzalez CD, Diez RA, Di Girolamo G.

Int J Clin Pharmacol Ther. 2014 Apr;52(4):292-302. doi: 10.5414/CP201957.

PMID:
24447650
15.

A recombinant human hyaluronidase sustained release gel for the treatment of post-surgical edema.

Nekoroski T, Paladini RD, Sauder DN, Frost GI, Keller GA.

Int J Dermatol. 2014 Jun;53(6):777-85. doi: 10.1111/ijd.12304. Epub 2013 Oct 29.

PMID:
24168080
16.

Adverse drug reactions as a reason for admission to an internal medicine ward in Argentina.

Alvarez PA, Bril F, Castro V, Meiville I, Gonzalez CD, Centurion IG, Parejas G, Riera CS, Saubidet CL, Di Girolamo G, Keller GA.

Int J Risk Saf Med. 2013;25(3):185-92. doi: 10.3233/JRS-130596.

PMID:
24047689
17.

Mutations in the catalytic domain of human matrix metalloproteinase-1 (MMP-1) that allow for regulated activity through the use of Ca2+.

Paladini RD, Wei G, Kundu A, Zhao Q, Bookbinder LH, Keller GA, Shepard HM, Frost GI.

J Biol Chem. 2013 Mar 1;288(9):6629-39. doi: 10.1074/jbc.M112.364729. Epub 2013 Jan 15.

18.

Severe neutropenia in a renal transplant patient suggesting an interaction between mycophenolate and fenofibrate.

Alvarez PA, Egozcue J, Sleiman J, Moretti L, Di Girolamo G, Keller GA.

Curr Drug Saf. 2012 Feb;7(1):24-9.

PMID:
22663953
19.

Reducing major depression in children at high risk: opportunities for prevention.

Keller GA, Gottlieb DT.

Int J Psychiatry Med. 2012;44(3):271-90. Review.

PMID:
23586281
20.

Pharmacovigilance and the cardiovascular system: two sides to every story.

Keller GA, Di Girolamo G, Alvarez PA.

Curr Drug Saf. 2011 Sep 1;6(4):224-9.

PMID:
22129317
21.

Relative bioavailability of a 5 mg mosapride/10 mg rabeprazole fixed dose combination tablet versus separate single tablets in healthy volunteers: a single-dose randomized open-label crossover study.

Keller GA, Czerniuk P, Bertuola R, de Mena F, Simoni MV, Assefi AR, Di Girolamo G.

Curr Med Res Opin. 2011 Nov;27(11):2203-11. doi: 10.1185/03007995.2011.624088. Epub 2011 Oct 4.

PMID:
21970660
22.

Comparative bioavailability of 2 tablet formulations of levodopa/benserazide in healthy, fasting volunteers: a single-dose, randomized-sequence, open-label crossover study.

Keller GA, Czerniuk P, Bertuola R, Spatz JG, Assefi AR, Di Girolamo G.

Clin Ther. 2011 Apr;33(4):500-10. doi: 10.1016/j.clinthera.2011.04.012.

PMID:
21635995
23.

Other drugs acting on nervous system associated with QT-interval prolongation.

Keller GA, Ponte ML, Di Girolamo G.

Curr Drug Saf. 2010 Jan;5(1):105-11. Review.

PMID:
20210727
24.

Prokinetic agents and QT prolongation: a familiar scene with new actors.

Keller GA, Di Girolamo G.

Curr Drug Saf. 2010 Jan;5(1):73-8. Review.

PMID:
20210722
25.

Antihistamines: past answers and present questions.

Keller GA, Di Girolamo G.

Curr Drug Saf. 2010 Jan;5(1):58-64. Review.

PMID:
20210720
26.

Mechanisms of drug induced QT interval prolongation.

Ponte ML, Keller GA, Di Girolamo G.

Curr Drug Saf. 2010 Jan;5(1):44-53. Review.

PMID:
20210718
27.

Bioequivalence of two tablet formulations of clopidogrel in healthy Argentinian volunteers: a single-dose, randomized-sequence, open-label crossover study.

Di Girolamo G, Czerniuk P, Bertuola R, Keller GA.

Clin Ther. 2010 Jan;32(1):161-70. doi: 10.1016/j.clinthera.2010.01.010.

PMID:
20171421
28.

Bioequivalence of two levothyroxine tablet formulations without and with mathematical adjustment for basal thyroxine levels in healthy Argentinian volunteers: a single-dose, randomized, open-label, crossover study.

Di Girolamo G, Keller GA, de Los Santos AR, Schere D, Gonzalez CD.

Clin Ther. 2008 Nov;30(11):2015-23. doi: 10.1016/j.clinthera.2008.11.005.

PMID:
19108789
29.

A recombinant human enzyme for enhanced interstitial transport of therapeutics.

Bookbinder LH, Hofer A, Haller MF, Zepeda ML, Keller GA, Lim JE, Edgington TS, Shepard HM, Patton JS, Frost GI.

J Control Release. 2006 Aug 28;114(2):230-41. Epub 2006 Jun 7.

PMID:
16876899
30.

[Abdomina distention and edema due to spermatic cord cyst].

Keller GA, Sessa C.

Medicina (B Aires). 2006;66(2):150-2. Spanish.

PMID:
16715766
31.
32.

Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate.

Ross S, Spencer SD, Holcomb I, Tan C, Hongo J, Devaux B, Rangell L, Keller GA, Schow P, Steeves RM, Lutz RJ, Frantz G, Hillan K, Peale F, Tobin P, Eberhard D, Rubin MA, Lasky LA, Koeppen H.

Cancer Res. 2002 May 1;62(9):2546-53.

33.

Purification of brain peroxisomes and localization of 3-hydroxy-3-methylglutaryl coenzyme A reductase.

Kovacs WJ, Faust PL, Keller GA, Krisans SK.

Eur J Biochem. 2001 Sep;268(18):4850-9.

34.

Identification of an angiogenic mitogen selective for endocrine gland endothelium.

LeCouter J, Kowalski J, Foster J, Hass P, Zhang Z, Dillard-Telm L, Frantz G, Rangell L, DeGuzman L, Keller GA, Peale F, Gurney A, Hillan KJ, Ferrara N.

Nature. 2001 Aug 30;412(6850):877-84.

PMID:
11528470
35.
36.
37.
38.

Pex22p of Pichia pastoris, essential for peroxisomal matrix protein import, anchors the ubiquitin-conjugating enzyme, Pex4p, on the peroxisomal membrane.

Koller A, Snyder WB, Faber KN, Wenzel TJ, Rangell L, Keller GA, Subramani S.

J Cell Biol. 1999 Jul 12;146(1):99-112.

39.

Pex19p interacts with Pex3p and Pex10p and is essential for peroxisome biogenesis in Pichia pastoris.

Snyder WB, Faber KN, Wenzel TJ, Koller A, Lüers GH, Rangell L, Keller GA, Subramani S.

Mol Biol Cell. 1999 Jun;10(6):1745-61.

40.

VEGF is required for growth and survival in neonatal mice.

Gerber HP, Hillan KJ, Ryan AM, Kowalski J, Keller GA, Rangell L, Wright BD, Radtke F, Aguet M, Ferrara N.

Development. 1999 Mar;126(6):1149-59.

41.

Peroxisome degradation by microautophagy in Pichia pastoris: identification of specific steps and morphological intermediates.

Sakai Y, Koller A, Rangell LK, Keller GA, Subramani S.

J Cell Biol. 1998 May 4;141(3):625-36.

43.

Effect of insulin-like growth factor binding proteins on the response of proximal tubular cells to insulin-like growth factor-I.

Yap J, Tsao T, Fawcett J, Fielder PJ, Keller GA, Rabkin R.

Kidney Int. 1997 Nov;52(5):1216-23.

44.

Normal platelets and megakaryocytes are produced in vivo in the absence of thrombopoietin.

Bunting S, Widmer R, Lipari T, Rangell L, Steinmetz H, Carver-Moore K, Moore MW, Keller GA, de Sauvage FJ.

Blood. 1997 Nov 1;90(9):3423-9.

45.

Characterization of UT2 cells. The induction of peroxisomal 3-hydroxy-3-methylglutaryl-coenzyme a reductase.

Engfelt WH, Shackelford JE, Aboushadi N, Jessani N, Masuda K, Paton VG, Keller GA, Krisans SK.

J Biol Chem. 1997 Sep 26;272(39):24579-87.

46.

Regulation of the serum concentration of thrombopoietin in thrombocytopenic NF-E2 knockout mice.

Shivdasani RA, Fielder P, Keller GA, Orkin SH, de Sauvage FJ.

Blood. 1997 Sep 1;90(5):1821-7.

47.

Insulin-degrading enzyme does not require peroxisomal localization for insulin degradation.

Chesneau V, Perlman RK, Li W, Keller GA, Rosner MR.

Endocrinology. 1997 Aug;138(8):3444-51.

PMID:
9231799
49.

Metabolism of thrombopoietin (TPO) in vivo: determination of the binding dynamics for TPO in mice.

Stefanich E, Senn T, Widmer R, Fratino C, Keller GA, Fielder PJ.

Blood. 1997 Jun 1;89(11):4063-70.

50.

Human platelets as a model for the binding and degradation of thrombopoietin.

Fielder PJ, Hass P, Nagel M, Stefanich E, Widmer R, Bennett GL, Keller GA, de Sauvage FJ, Eaton D.

Blood. 1997 Apr 15;89(8):2782-8.

Supplemental Content

Loading ...
Support Center